Modest advances in survival for patients with colorectal-associated peritoneal carcinomatosis in the era of modern chemotherapy

Journal of Surgical Oncology

Volumn 107, Issue 4, 2013, Pages 307-311

  Zani, Sabino ^a   Papalezova, Katia ^b   Stinnett, Sandra ^c   Tyler, Douglas ^a   Hsu, David ^c   Blazer III, Dan G ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

colorectal cancer; cytoreduction; HIPEC; peritoneal carcinomatosis

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; PANITUMUMAB;

ADULT; AGE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CARCINOMATOUS PERITONITIS; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL AGENTS; CAMPTOTHECIN; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASMS, MULTIPLE PRIMARY; NEOPLASMS, SECOND PRIMARY; ORGANOPLATINUM COMPOUNDS; PATIENT SELECTION; PERITONEAL NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES;

EID: 84874263740     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23222     Document Type: Article

References (30)

1. Tournigand C, Andre T, Achille E, et al.: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004; 22: 229-237.
2. Howlader N, Noone AM, Krapcho M, et al.: editors. SEER cancer statistics review, 1975-2008. Bethesda, MD: National Cancer Institute; http://seer.cancer. gov/csr/1975-2008/, based on November 2010 SEER data submission, posted to the SEER web site, 2011. 2011.
3. Chu DZ, Lang NP, Thompson C, et al.: Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer 1989; 63: 364-367.
4. Sadeghi B, Arvieux C, Glehen O, et al.: Peritoneal carcinomatosis from non-gynecologic malignancies: Results of the EVOCAPE 1 multicentric prospective study. Cancer 2000; 88: 358-363.
5. Esquivel J:, Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of peritoneal surface malignancies of colonic origin. Appl Cancer Res 2007; 27: 136-143.
6. Koppe MJ, Boerman OC, Oyen WJ, et al.: Peritoneal carcinomatosis of colorectal origin: Incidence and current treatment strategies. Ann Surg 2006; 243: 212-222.
7. Jayne DG, Fook S, Loi C, et al.: Peritoneal carcinomatosis from colorectal cancer. Br J Surg 2002; 89: 1545-1550.
8. Verwaal VJ, van Ruth S, de Bree E, et al.: Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21: 3737-3743.
9. Cunningham D, Humblet Y, Siena S, et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
10. Grothey A, Sargent D, Goldberg RM, et al.: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22: 1209-1214.
11. Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
12. Fuchs CS, Marshall J, Barrueco J:, Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Updated results from the BICC-C study. J Clin Oncol: Official journal of the American Society of Clinical Oncology 2008; 26: 689-690.
13. Giantonio BJ, Catalano PJ, Meropol NJ, et al.: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol: Official journal of the American Society of Clinical Oncology 2007; 25: 1539-1544.
14. Hochster HS, Hart LL, Ramanathan RK, et al.: Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE Study. J Clin Oncol: Official journal of the American Society of Clinical Oncology 2008; 26: 3523-3529.
15. Saltz LB, Clarke S, Diaz-Rubio E, et al.: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
16. Douillard JY, Siena S, Cassidy J, et al.: Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol 2010; 28: 4697-4705.
17. Peeters M, Price TJ, Cervantes A, et al.: Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol: Official journal of the American Society of Clinical Oncology 2010; 28: 4706-4713.
18. Van Cutsem E, Kohne CH, Hitre E, et al.: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417.
19. Bokemeyer C, Bondarenko I, Makhson A, et al.: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol: Official journal of the American Society of Clinical Oncology 2009; 27: 663-671.
20. Maughan TS, Adams RA, Smith CG, et al.: Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: Results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377: 2103-2114.
21. Verwaal VJ, Bruin S, Boot H, et al.: interen H. 8-year follow-up of randomized trial: Cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008; 15: 2426-2432.
22. Elias D, Gilly F, Boutitie F, et al.: Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: Retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 2010; 28: 63-68.
23. de Gramont A, Figer A, Seymour M, et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
24. Giacchetti S, Perpoint B, Zidani R, et al.: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136-147.
25. Franko J, Shi Q, Goldman CA, et al.: Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: A pooled analysis of NCCTG's phase III trials N9741 and N9841. J Clin Oncol 2012; 30: 263-267.
26. Hompes D, Boot H, van Tinteren H, et al.: Unresectable peritoneal carcinomatosis from colorectal cancer: A single center experience. J Surg Oncol 2011; 104: 269-273.
27. Elias D, Lefevre JH, Chevalier J, et al.: Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2009; 27: 681-685.
28. Franko J, Ibrahim Z, Gusani NJ, et al.: Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer 2010; 116: 3756-3762.
29. Esquivel J, Sticca R, Sugarbaker P, et al.: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: A consensus statement. Society of Surgical Oncology. Ann Surg Oncol 2007; 14: 128-133.
30. Esquivel J, Elias D, Baratti D, et al.: Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination. J Surg Oncol 2008; 98: 263-267.